Greenyn Biotechnology Co

Greenyn Biotechnology Co FCF Margin

The Free Cash Flow Margin of Greenyn Biotechnology Co (6846.TWO) as of Nov 2, 2026 is -25.80 %. In the previous year, Free Cash Flow Margin was 24.04 % — a change of -207.35% (lower).

FCF Margin

-25.80 %

YoY

-207.35%

Last updated:

Free Cash Flow Margin of Greenyn Biotechnology Co is 2025 -25.80 % . Free Cash Flow Margin of Greenyn Biotechnology Co was 2024 24.04 % . It decreases by -207.35% lower compared to the previous year.

The Greenyn Biotechnology Co FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2019
19.13 TWD
Jan 1, 2020
37.70 TWD
Jan 1, 2021
9.23 TWD
Jan 1, 2022
30.14 TWD
Jan 1, 2023
4.71 TWD
Jan 1, 2024
24.04 TWD
Jan 1, 2025
-25.80 TWD
The Greenyn Biotechnology Co FCF Margin history
YEARFCF MarginYoY
-25.80 %-207.35%
24.04 %+409.93%
4.71 %-84.36%
30.14 %+226.46%
9.23 %-75.51%
37.70 %+97.05%
19.13 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Greenyn Biotechnology Co Stock analysis

What does Greenyn Biotechnology Co do? Greenyn Biotechnology Co., Ltd. generates revenue through the research, development, manufacture, and sales of health food raw materials across three business segments: health ingredients, health formulations, and other segments. Its main products include Antrodia cinnamomea mycelia, Bitter melon extract (Insumate), and 101 Phyto Fermented Drink, which are primarily sold in Taiwan and other Asian regions. The company focuses on supplying these health-focused products to customers within the Asian market, leveraging its product portfolio for regional demand. The firm's product lineup targets health-conscious consumers seeking natural health solutions, with Antrodia cinnamomea mycelia and Bitter melon extract (Insumate) serving as key offerings. 101 Phyto Fermented Drink represents another core product, emphasizing plant-based health benefits. These products are distributed through established channels in Taiwan and neighboring Asian markets, supporting the company's regional sales strategy. Greenyn Biotechnology's business model centers on developing and commercializing specialized health ingredients and formulations, with a strong emphasis on Asian market penetration. The company's revenue streams are derived from the direct sale of its proprietary health food raw materials to customers in Taiwan and other Asian regions, without mentioning external partners or additional distribution channels beyond the specified markets. Greenyn Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Greenyn Biotechnology Co stock

Free Cash Flow Margin of Greenyn Biotechnology Co is -25.80 % in 2025.

Free Cash Flow Margin of Greenyn Biotechnology Co changed from 24.04 % to -25.80 %, representing a -207.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Greenyn Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Greenyn Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Greenyn Biotechnology Co

All Key Metrics — Greenyn Biotechnology Co